



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/903,377	07/10/2001	Keith D. Allen	R-365	8328

7590
DELTAGEN, INC.
1003 Hamilton Avenue
Menlo Park, CA 94025

12/05/2003



EXAMINER


PARAS JR, PETER


ART UNIT PAPER NUMBER

1632

DATE MAILED: 12/05/2003

Please find below and/or attached an Office communication concerning this application or proceeding.





Office Action Summary

Application No.

09/903,377

Applicant(s)

ALLEN, KEITH D.

Examiner

Peter Paras, Jr.

Art Unit

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11 August 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-7, 11-16 and 23-39 is/are pending in the application.
- 4a) Of the above claim(s) 1-7, 11-16 and 23-30 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 31-39 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s) _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

The amendment received on 8/11/03 has been entered. Claims 8-10 and 17-22 have been cancelled. New claims 31-39 have been added. Claims 1-7, 11-16 and 23-39 are pending. Claims 31-39 are under current examination.

Upon further consideration the following are new grounds of rejection under 35 U.S.C. 101:

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 31-39 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility.

The claims are directed to a transgenic mouse whose genome comprises a disruption in an endogenous chemokine receptor 9A gene, wherein said mouse exhibits decreased agility, coordination or balance.

The instant specification has contemplated that the nucleotide sequence set forth in SEQ ID NO: 1 encodes a chemokine receptor 9A. The instant specification has further contemplated that disruption of the nucleotide sequence set forth in SEQ ID NO: 1 in a mouse will produce a phenotype related to chemokine receptor 9A. The instant specification has purported that such mice may be used to identify agents that modulate or ameliorate a phenotype associated with a disruption in SEQ ID NO: 1.

The instant specification has disclosed a transgenic mouse whose genome comprises a disruption in SEQ ID NO: 1, wherein the mouse exhibits decreased agility, coordination or balance. The claims embrace such a mouse and a method of making the mouse. The instant specification has discussed that phenotypes (decreased agility, coordination or balance) exhibited by such a transgenic mouse could correlate to a disease or disorder. However, the evidence of record does not provide a correlation between decreased agility, coordination or balance and any disease or disorder. Moreover, while the specification has purported that the nucleotide sequence set forth in SEQ ID NO: 1 encodes a chemokine receptor 9A, the evidence of record has failed to provide a correlation between any chemokine receptor 9A related disease/disorder and decreased agility, coordination or balance. The specification has provided general assertions that the claimed transgenic mice may be used to identify agents that affect a phenotype related to the mice.

As such, the asserted utility, for the transgenic mouse embraced by the claims, of screening agents that may affect a phenotype of said mouse as provided by the instant specification and encompassed by the claims, does not appear to be specific and substantial. The asserted utility does not appear specific and substantial to the skilled artisan since the evidence of record has not provided any suggestion of a correlation between any chemokine receptor 9A, decreased agility, coordination or balance, and any disease or disorder. Since the evidence of record has not provided a correlation between decreased agility, coordination or balance and any disease or disorder, the utility of identifying agents that affect decreased agility, coordination or balance is not

apparent. The evidence of record has not provided any other utilities for the transgenic mouse embraced by the claims that are specific, substantial, and credible.

The asserted utility of the transgenic mouse embraced by the claims is based on the expectation that disrupting the nucleotide sequence set forth in SEQ ID NO: 1 would result in a detectable phenotype in the mouse. The phenotype observed in the transgenic mice embraced by the claims is decreased agility, coordination or balance. While the phenotypes exhibited by the claimed transgenic mouse are contemplated to be associated with a disease, the association of decreased agility, coordination or balance with any disease has yet to be elucidated. In fact the art suggests that results obtained from behavioral studies are greatly influenced by the genetic background of the tested mouse. Crabbe et al (Science, 1999, Vol. 284, pages 1670-1672) observed that laboratory environment and site, test conditions, and genetic strain of a mouse could influence the results of behavioral studies, such as the rotarod. See pages 1670-1671. For example, Crabbe reports in open field testing, A/J mice were relatively inactive, while C57BL/6 mice were very active. Crabbe further reports that on average mice tested in Edmonton were more active than those tested in Albany or Portland. See page 1671, column 1, the first full paragraph. Crabbe discusses that such inconsistencies in test results can be responsible for observed behavioral phenotypes. Given the inconsistencies in behavioral test results, Crabbe concludes by cautioning that specific behavioral effects observed in mutant (knockout) mice should be not be uncritically attributed to genetic manipulations prior to repeating testing in different

Art Unit: 1632

laboratories using different strains of mice, if possible. See page 1672, column 1, paragraphs 2-3.

Therefore, the references suggest a need to provide independent evidence of an association of decreased agility, coordination or balance with a disease or disorder. However, neither the specification nor any art of record provides evidence of the existence of a correlation between decreased agility, coordination or balance and a disease or disorder, leaving the skilled artisan to speculate and investigate the uses of the transgenic mouse embraced by the claims. The specification essentially gives an invitation to experiment wherein the artisan is invited to elaborate a functional use for the transgenic mouse embraced by the claims. In light of the above, the skilled artisan would not find the asserted utility of the transgenic mouse embraced by the claims to be specific and substantial.

Claim Rejections - 35 USC § 112, 1st paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 31-39 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Claim Rejections - 35 USC § 112, 2nd paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 38-39 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 38 is directed to a method of producing a transgenic mouse, wherein method step (a) recites introducing a chemokine receptor 9A gene targeting construct into a murine embryonic stem cell. However, the term murine encompasses both mice and rats. The claim is indefinite because it is unclear how a transgenic mouse can be produced when using a rat embryonic stem cell. It appears that Applicants have inadvertently used improper terminology to describe a mouse embryonic stem cell. Appropriate correction is required. Amending the claim to read on a mouse embryonic stem cell will obviate this rejection. Claim 39 depends from claim 38.

Conclusion

No claim is allowed.

Art Unit: 1632

Any inquiry concerning this communication or earlier communications from the examiner(s) should be directed to Peter Paras, Jr., whose telephone number is 703-308-8340. The examiner can normally be reached Monday-Friday from 8:30 to 4:30 (Eastern time). The examiner is scheduled to move a new office, on 1/13/2004, having a new telephone number as follows: 571-272-0732.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached at 703-305-4051. Papers related to this application may be submitted by facsimile transmission. Papers should be faxed via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Official Fax Center number is (703) 872-9306.

Inquiries of a general nature or relating to the status of the application should be directed to Dianiece Jacobs whose telephone number is (703) 305-3388.

Peter Paras, Jr.

Art Unit 1632

PETER PARAS
PATENT EXAMINER

